Eagle Pharmaceuticals Announces Submission of New Drug Application to U.S. Food and Drug Administration for Landiolol, a Beta-1 Adrenergic Blocker

Submission seeks approval for landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter Expected approval mid-year 2023, if accepted by FDA for...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news